Boehringer Ingelheim's "female Viagra" shows mixed results in Phase III
This article was originally published in Scrip
Boehringer Ingelheim's once-daily 5-HT1A agonist and 5-HT2A antagonist flibanserin has demonstrated mixed results in four pivotal Phase III trials – DAISY, VIOLET, DAHLIA and ORCHID – examining the drug's effects on the number of satisfying sexual events (SSEs),sexual desire and the distress associated with hypoactive sexual desire disorder (HSDD) in pre-menopausal women.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.